Fycompa
Drug
Eisai Inc.
Total Payments
$22.0M
Transactions
73,972
Doctors
8,277
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $291,451 | 51 | 4 |
| 2023 | $957,260 | 2,654 | 1,436 |
| 2022 | $1.3M | 12,170 | 3,423 |
| 2021 | $2.7M | 11,822 | 3,174 |
| 2020 | $2.8M | 6,169 | 1,930 |
| 2019 | $4.9M | 12,903 | 2,650 |
| 2018 | $4.6M | 14,280 | 3,025 |
| 2017 | $4.4M | 13,923 | 3,382 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.8M | 2,680 | 53.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.7M | 3,172 | 26.0% |
| Consulting Fee | $1.7M | 747 | 7.8% |
| Food and Beverage | $1.5M | 62,582 | 6.7% |
| Travel and Lodging | $1.1M | 3,972 | 5.0% |
| Space rental or facility fees (teaching hospital only) | $131,150 | 66 | 0.6% |
| Grant | $85,000 | 10 | 0.4% |
| Education | $17,181 | 741 | 0.1% |
| Honoraria | $3,000 | 2 | 0.0% |
Payments by Type
Research
$11.8M
2,680 transactions
General
$10.2M
71,292 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome | Eisai Inc. | $1.7M | 0 |
| A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy | Eisai Inc. | $1.3M | 0 |
| An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic Clonic Seizures | Eisai Inc. | $1.3M | 0 |
| An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy | Eisai Inc. | $1.2M | 0 |
| Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures | Eisai Inc. | $904,057 | 0 |
| Single Site Study to determine Fycompa time in therapeutic range following discontinuation after achieving steady state in healthy volunteers | Eisai Inc. | $501,515 | 0 |
| Fycompa in the treatment of Benzodiazepine-Refractory Status Epilepticus | Eisai Inc. | $395,000 | 0 |
| Effects of Titration Rate on Cognitive and Behavioral Side Effects of Perampanel | Eisai Inc. | $381,264 | 0 |
| An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy | Eisai Inc. | $370,876 | 0 |
| Human Epilepsy Project | Eisai Inc. | $330,000 | 0 |
| Comparative efficacy of Perampanel, levetiracetam and locasamide in the post-status epilepticus model of epilepsy and the impact of variable medication adherence on seizure control | Eisai Inc. | $310,740 | 0 |
| Single Site Study to determine Fycompa time in therapeutic range following discontinuation after achieving steady state in healthy volunteers | Eisai Inc. | $251,000 | 0 |
| An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy | Eisai Inc. | $208,843 | 0 |
| An Open-Label Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Perampanel (E2007) in Subjects with Cervical Dystonia (SAFE-Per CD) | Eisai Inc. | $156,750 | 0 |
| Effects of Perampanel on Neurophysiology Test Perimeters | Eisai Inc. | $107,243 | 0 |
| Antiepileptogenesis study | Eisai Inc. | $106,656 | 0 |
| Effectiveness of Perampanel in Post-Traumatic Epilepsy | Eisai Inc. | $100,650 | 0 |
| Clinical decision-making and Fycompa administration in pediatric patients in the management of intractable epilepsy at a tertiary center | Eisai Inc. | $100,074 | 0 |
| A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel for Essential Tremor | Eisai Inc. | $98,102 | 0 |
| Perampanel as a neuroprotective and antiepileptic compound in animal model of traumatic brain injury (TBI) | Eisai Inc. | $91,571 | 0 |
Top Doctors Receiving Payments for Fycompa
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Ismail Mohamed | — | Cincinnati, OH | $12.0M | 2,787 |
| , MD | Neurology | Nashville, TN | $486,398 | 669 |
| , MD | Neurology with Special Qualifications in Child Neurology | Indianapolis, IN | $409,012 | 665 |
| , MD | Neurology | Tampa, FL | $389,982 | 639 |
| , M.D | Clinical Neurophysiology | Wayne, MI | $387,715 | 642 |
| , MD | Neurology | Cincinnati, OH | $343,475 | 515 |
| , MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $322,155 | 434 |
| , M.D | Neurology | Fort Wayne, IN | $291,805 | 384 |
| , MD | Neurology | Cleveland, OH | $290,598 | 275 |
| , MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $272,052 | 342 |
| , MD | Neurology | Houston, TX | $207,343 | 306 |
| , MD | Sleep Medicine | Sarasota, FL | $174,420 | 230 |
| , MD | Neurology with Special Qualifications in Child Neurology | Miami, FL | $169,739 | 193 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Cleveland, OH | $143,369 | 175 |
| , M.D | Neurology | Phoenix, AZ | $142,825 | 236 |
| , M.D | Neurology | Los Angeles, CA | $128,090 | 144 |
| , M.D | Specialist | Brooklyn, NY | $126,382 | 202 |
| , MD | Neurology | Sacramento, CA | $118,361 | 175 |
| , MD | Neurology | Bethesda, MD | $118,264 | 177 |
| , M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $117,576 | 105 |
| , M.D | Neurology | San Francisco, CA | $105,536 | 174 |
| , M.D | Neurology | Chesterfield, MO | $103,489 | 148 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Savannah, GA | $98,956 | 146 |
| Shahin Nouri | — | Brooklyn, NY | $95,805 | 130 |
| , MD | Neurology with Special Qualifications in Child Neurology | Covington, LA | $88,893 | 119 |
Ad
Manufacturing Companies
- Eisai Inc. $18.4M
- EISAI INC. $3.5M
- Eisai Co., Ltd. $107,315
- EISAI CO., LTD. $21,740
- Hikma Pharmaceuticals USA $4,000
Product Information
- Type Drug
- Total Payments $22.0M
- Total Doctors 8,277
- Transactions 73,972
About Fycompa
Fycompa is a drug associated with $22.0M in payments to 8,277 healthcare providers, recorded across 73,972 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2017 to 2024. In 2024, $291,451 was paid across 51 transactions to 4 doctors.
The most common payment nature for Fycompa is "Unspecified" ($11.8M, 53.5% of total).
Fycompa is associated with 20 research studies, including "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome" ($1.7M).